The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.
Guselkumab
Psoriatic arthritis
Therapy
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
18
12
2023
accepted:
06
02
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a "real-life" multicentre patient cohort. We also estimated the drug retention rate (DRR) of gusulkumab, also assessing the impact of comorbidities and patient clinical characteristics, in a collective 18-month prospective follow-up. Between December 2021 and September 2023, consecutive patients with PsA were evaluated if treated at least for 6 months with guselkumab in a prospective multicentre study to evaluate the effectiveness of the drug by means of disease activity index for psoriatic arthritis (DAPSA) and cumulative DRR. A total of 111 patients with PsA were evaluated and treated with guselkumab (age 56.8 ± 9.9, male sex 20.7%). These patients were mainly characterised by active and long-standing PsA with median disease duration of 6.0 (7.0) years (55.9% disease duration ≥ 5 years), 55.0% showed comorbidities, 78.4% of patients were previously treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs), and 60.4% concomitantly with conventional synthetic DMARDs (csDMARDs). After 6 months, a significant reduction of DAPSA was observed (β - 15.47, p = 0.001, 95% CI - 23.15 to - 9.79) with 39.6% of patients achieving a DAPSA ≤ 14. At the end of cumulative follow-up, 71.2% of patients were still treated with guselkumab whereas 24.3% discontinued the drug because of inefficacy. An 18-month DRR of guselkumab of 66.7% was estimated with a mean time of administration of 9.8 ± 4.1 months. The results of the DRR were stratified according to patient clinical characteristics. The DRR of guselkumab appeared to be not influenced by long disease duration, comorbidities, obesity, concomitant csDMARDs, and previous bDMARDs. The "real-life" 6-month effectiveness of guselkumab was shown in patients with PsA, mainly characterised by active long-standing disease, previously treated with bDMARDs, and with comorbidities. Furthermore, a good DRR of guselkumab was estimated in the cumulative 18 months of follow-up and appeared to be not influenced by long disease duration, comorbidities, obesity, and previous bDMARDs.
Identifiants
pubmed: 38436915
doi: 10.1007/s40744-024-00649-2
pii: 10.1007/s40744-024-00649-2
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59. https://doi.org/10.1038/s41572-021-00293-y .
doi: 10.1038/s41572-021-00293-y
Ruscitti P, Esposito M, Gianneramo C, et al. Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study. Radiol Med. 2022;127(12):1400–6. https://doi.org/10.1007/s11547-022-01568-4 .
doi: 10.1007/s11547-022-01568-4
Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 2021;51(4):880–7. https://doi.org/10.1016/j.semarthrit.2021.06.006 .
doi: 10.1016/j.semarthrit.2021.06.006
Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2199–206. https://doi.org/10.1093/rheumatology/keaa062 .
doi: 10.1093/rheumatology/keaa062
Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792–7. https://doi.org/10.1093/rheumatology/keu398 .
doi: 10.1093/rheumatology/keu398
Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis - a perspective. Expert Rev Clin Immunol. 2020;16(10):963–72. https://doi.org/10.1080/1744666X.2021.1825941 .
doi: 10.1080/1744666X.2021.1825941
Caso F, Chimenti MS, Navarini L, et al. Metabolic syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol. 2020;16(4):409–20. https://doi.org/10.1080/1744666X.2020.1740593 .
doi: 10.1080/1744666X.2020.1740593
Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311–25. https://doi.org/10.1038/s41584-022-00776-6 .
doi: 10.1038/s41584-022-00776-6
Ruscitti P, Esposito M, Di Cola I, et al. Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum. Front Immunol. 2023;13(14):1229516. https://doi.org/10.3389/fimmu.2023.1229516 .
doi: 10.3389/fimmu.2023.1229516
Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol. 2021;7(11):596086. https://doi.org/10.3389/fimmu.2020.596086 .
doi: 10.3389/fimmu.2020.596086
Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022;20 Suppl 1(Suppl 1):S12–21. https://doi.org/10.1002/msc.1694 .
doi: 10.1002/msc.1694
Ritchlin C. Navigating the diverse immune landscapes of psoriatic arthritis. Semin Immunopathol. 2021;43(2):279–90. https://doi.org/10.1007/s00281-021-00848-x .
doi: 10.1007/s00281-021-00848-x
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12. https://doi.org/10.1136/annrheumdis-2020-217159 .
doi: 10.1136/annrheumdis-2020-217159
Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79. https://doi.org/10.1038/s41584-022-00798-0 . (Erratum in: Nat Rev Rheumatol. 2022 Oct 10).
doi: 10.1038/s41584-022-00798-0
Huang X, Shentu H, He Y, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023. https://doi.org/10.1007/s12026-023-09366-4 .
doi: 10.1007/s12026-023-09366-4
Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–25. https://doi.org/10.1016/S0140-6736(20)30265-8 . (Erratum in: Lancet. 2020 Apr 4;395(10230):1114).
doi: 10.1016/S0140-6736(20)30265-8
Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2) a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36. https://doi.org/10.1016/S0140-6736(20)30263-4 . (Erratum in: Lancet. 2020 Apr 4;395(10230):1114).
doi: 10.1016/S0140-6736(20)30263-4
Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359–69. https://doi.org/10.1136/annrheumdis-2021-220991 .
doi: 10.1136/annrheumdis-2021-220991
Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74. https://doi.org/10.1007/s12325-018-0805-y .
doi: 10.1007/s12325-018-0805-y
Barnish MS, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;12(8):49–55. https://doi.org/10.2147/POR.S137701 .
doi: 10.2147/POR.S137701
Batrouni M, Comet D, Meunier JP. Real world studies, challenges, needs and trends from the industry. Value Health. 2014;17(7):A587–8. https://doi.org/10.1016/j.jval.2014.08.2006 .
doi: 10.1016/j.jval.2014.08.2006
Pantano I, Mauro D, Romano F, et al. Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology (Oxford). 2022;61(3):1217–21. https://doi.org/10.1093/rheumatology/keab509 .
doi: 10.1093/rheumatology/keab509
Rocamora V, Crespi L, Ferran M, et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(11):e15865. https://doi.org/10.1111/dth.15865 .
doi: 10.1111/dth.15865
Vaiopoulos AG, Dalamaga M, Katsimbri P, Koumourtzis M, Lampadaki K, Theodoropoulos K, Theotokoglou S, Kanelleas A, Syrmali A, Filippopoulou A, Zoupidou K, Katoulis A, Papadavid E. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404–1413. https://doi.org/10.1111/ijd.16849 .
doi: 10.1111/ijd.16849
Mease PJ, Ogdie A, Chakravarty SD, et al. Clinical characteristics of registry participants with psoriatic arthritis initiating guselkumab: an analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes. 2022;9(4):617–28. https://doi.org/10.1007/s40801-022-00326-2 .
doi: 10.1007/s40801-022-00326-2
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. https://doi.org/10.1002/art.21972 .
doi: 10.1002/art.21972
Rahman P, Boehncke WH, Mease PJ, et al. Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol. 2023;50(6):769–80. https://doi.org/10.3899/jrheum.220928 .
doi: 10.3899/jrheum.220928
Mease PJ, Ogdie A, Tesser J, et al. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2023;10(6):1479–501. https://doi.org/10.1007/s40744-023-00582-w .
doi: 10.1007/s40744-023-00582-w
Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715–23.
doi: 10.1016/S2665-9913(21)00105-3
Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled discover-2 study. Rheumatol Ther. 2023;10(6):1637–53. https://doi.org/10.1007/s40744-023-00592-8 .
doi: 10.1007/s40744-023-00592-8
Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain Efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled discover-1 study. ACR Open Rheumatol. 2023;5(3):149–64. https://doi.org/10.1002/acr2.11523 .
doi: 10.1002/acr2.11523
Braun J, Landewé RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “physician-reported spondylitis”? Ann Rheum Dis. 2022;81(4):466–8. https://doi.org/10.1136/annrheumdis-2021-221422 .
doi: 10.1136/annrheumdis-2021-221422
Siebert S, Behrens F, Lubrano E, et al. PsABIOnd study and eDaily substudy design: long-term effectiveness and safety of guselkumab and IL-17 inhibitors in routine clinical practice in patients with psoriatic arthritis. Rheumatol Ther. 2023;10(2):489–505. https://doi.org/10.1007/s40744-022-00518-w .
doi: 10.1007/s40744-022-00518-w
Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531. https://doi.org/10.1080/09546634.2022.2133531 .
doi: 10.1080/09546634.2022.2133531
Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513–26. https://doi.org/10.1038/s41584-022-00810-7 .
doi: 10.1038/s41584-022-00810-7
Novelli L, Lubrano E, Venerito V, et al. Extra-articular manifestations and comorbidities in psoriatic disease: a journey into the immunologic crosstalk. Front Med (Lausanne). 2021;23(8):737079. https://doi.org/10.3389/fmed.2021.737079 .
doi: 10.3389/fmed.2021.737079
Panagiotopoulos A, Fragoulis GE. Comorbidities in psoriatic arthritis: a narrative review. Clin Ther. 2023;45(2):177–89. https://doi.org/10.1016/j.clinthera.2023.01.006 .
doi: 10.1016/j.clinthera.2023.01.006
Duffield SJ, Ellis BM, Goodson N, et al. The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy. Best Pract Res Clin Rheumatol. 2017;31(2):129–44. https://doi.org/10.1016/j.berh.2017.09.004 .
doi: 10.1016/j.berh.2017.09.004
Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016;55(12):2191–9. https://doi.org/10.1093/rheumatology/kew326 .
doi: 10.1093/rheumatology/kew326
Galíndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clin. 2016;12(6):307–12. https://doi.org/10.1016/j.reuma.2015.12.005 .
doi: 10.1016/j.reuma.2015.12.005
Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev. 2023;22(7):103357. https://doi.org/10.1016/j.autrev.2023.103357 .
doi: 10.1016/j.autrev.2023.103357
Strober B, Coates LC, Lebwohl MG, et al. Long-Term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2023. https://doi.org/10.1007/s40264-023-01361-w .
doi: 10.1007/s40264-023-01361-w
Giacomelli R, Afeltra A, Bartoloni E, et al. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and experts’ consensus. Autoimmun Rev. 2021;20(2):102738. https://doi.org/10.1016/j.autrev.2020.102738 .
doi: 10.1016/j.autrev.2020.102738
Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911–24. https://doi.org/10.1016/j.autrev.2017.07.012 .
doi: 10.1016/j.autrev.2017.07.012